ArticleDermatology and therapy2026
International Validation of the Short Version of the Quality of Life Relevance-Acne Questionnaire.
Article in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe objective of the present study was to conduct an international validation of the Quality of Life Relevance-Acne Short Version (QOLRELEVANCE-ACNE-SV) and to propose a severity grading system for its scores.
methodsAll patients were asked to fill in the QOLRELEVANCE-ACNE-SV and Dermatology Life Quality Index (DLQI). Global acne severity was assessed separately by dermatologists and patients. Students without acne were asked to fill in the QOLRELEVANCE-ACNE-SV questionnaire on a voluntary basis.
resultsThe results of 530 patients with acne across five countries that collected more than 100 results each (Croatia, Greece, Ukraine, Turkey and Romania) were analysed. The results from France, Bulgaria and Malta that collected fewer results were used for assessment of internal consistency. The results from Bulgaria were also used to check test-retest reliability. Cronbach's alpha was 0.84-0.95 in all countries except Bulgaria and Malta (0.74 and 0.75, respectively). Correlations between QOLRELEVANCE-ACNE-SV scores and DLQI scores were 0.54-0.85 except for Turkey (0.33); mean global acne severity assessed by a dermatologist 0.44-0.90 and self-assessment of the global acne severity 0.45-0.88 except for Romania (0.28 and 0.38, respectively). Among volunteers without acne, all QOLRELEVANCE-ACNE-SV questionnaire scores were 0. Test-retest reliability of the QOLRELEVANCE-ACNE-SV was good (r = 0.90, p < 0.001). The following grading system of the QOLRELEVANCE-ACNE-SV scores was accepted: total scores < 6 correspond to a mild effect, scores from 6 to 8 correspond to moderate effect and scores > 8 correspond to severe effect on a patient's life.
conclusionsOur study confirmed high specificity of the QOLRELEVANCE-ACNE-SV questionnaire for patients with acne, good test-retest reliability, good or excellent internal consistency in all countries except Bulgaria and Malta, where it rated as acceptable, good or moderate convergent validity with DLQI (except Turkey) and with global acne severity (except Romania). A grading system of the QOLRELEVANCE-ACNE-SV questionnaire scores was accepted.
Indexed as
Identifiers
42821226What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.